Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
CNY 7.83
(0.51%)
CNY 7.83
(0.51%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 816.76 Million CNY | 5.97% |
| 2022 | 764.54 Million CNY | 34.2% |
| 2021 | 569.69 Million CNY | 39.21% |
| 2020 | 409.24 Million CNY | 32.91% |
| 2019 | 307.91 Million CNY | 26.25% |
| 2018 | 243.88 Million CNY | 1.54% |
| 2017 | 240.18 Million CNY | 20.79% |
| 2016 | 198.84 Million CNY | -24.3% |
| 2015 | 262.66 Million CNY | 30.41% |
| 2014 | 201.41 Million CNY | 66.53% |
| 2013 | 120.94 Million CNY | 105.24% |
| 2012 | 58.93 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 188.83 Million CNY | -36.86% |
| 2024 Q1 | 299.05 Million CNY | 109.19% |
| 2024 Q3 | 196.12 Million CNY | 3.86% |
| 2023 Q2 | 206.16 Million CNY | -21.48% |
| 2023 Q3 | 202.94 Million CNY | -1.56% |
| 2023 FY | 810.2 Million CNY | 5.97% |
| 2023 Q1 | 262.54 Million CNY | 40.68% |
| 2023 Q4 | 142.95 Million CNY | -29.56% |
| 2022 Q4 | 186.63 Million CNY | -5.05% |
| 2022 Q2 | 176.24 Million CNY | -14.07% |
| 2022 Q1 | 205.11 Million CNY | 46.49% |
| 2022 FY | 764.54 Million CNY | 34.2% |
| 2022 Q3 | 196.55 Million CNY | 11.52% |
| 2021 Q2 | 141.65 Million CNY | -1.62% |
| 2021 FY | 569.69 Million CNY | 39.21% |
| 2021 Q1 | 143.99 Million CNY | 34.1% |
| 2021 Q4 | 140.01 Million CNY | -2.79% |
| 2021 Q3 | 144.03 Million CNY | 1.68% |
| 2020 Q3 | 91.99 Million CNY | -29.45% |
| 2020 Q2 | 130.4 Million CNY | 64.09% |
| 2020 FY | 409.24 Million CNY | 32.91% |
| 2020 Q1 | 79.47 Million CNY | -23.94% |
| 2020 Q4 | 107.37 Million CNY | 16.72% |
| 2019 Q3 | 74.17 Million CNY | 4.65% |
| 2019 Q2 | 70.88 Million CNY | 21.45% |
| 2019 Q1 | 58.36 Million CNY | -34.88% |
| 2019 FY | 307.91 Million CNY | 26.25% |
| 2019 Q4 | 104.48 Million CNY | 40.86% |
| 2018 Q1 | 49.87 Million CNY | -50.37% |
| 2018 Q3 | 38.16 Million CNY | -42.37% |
| 2018 Q2 | 66.21 Million CNY | 32.75% |
| 2018 FY | 243.88 Million CNY | 1.54% |
| 2018 Q4 | 89.63 Million CNY | 134.89% |
| 2017 FY | 240.18 Million CNY | 20.79% |
| 2017 Q3 | 49.16 Million CNY | -4.69% |
| 2017 Q2 | 51.58 Million CNY | 32.43% |
| 2017 Q1 | 38.95 Million CNY | -49.71% |
| 2017 Q4 | 100.49 Million CNY | 104.41% |
| 2016 Q1 | 41.1 Million CNY | 0.0% |
| 2016 Q3 | 48.08 Million CNY | 49.29% |
| 2016 Q2 | 32.2 Million CNY | -21.64% |
| 2016 Q4 | 77.44 Million CNY | 61.07% |
| 2016 FY | 198.84 Million CNY | -24.3% |
| 2015 FY | 262.66 Million CNY | 30.41% |
| 2015 Q1 | 45.16 Million CNY | 0.0% |
| 2014 FY | 201.41 Million CNY | 66.53% |
| 2013 FY | 120.94 Million CNY | 105.24% |
| 2012 FY | 58.93 Million CNY | 0.0% |